Iterum Therapeutics (ITRMF) Q3 2025 Earnings Report

951 Followers

Previous Report: Q2 2025

Next Report: Q4 2025

ITRMF Q3 2025 EPS Results

Actual EPS-$0.16

Consensus EPS-$0.09

Beat/MissMissed by -$0.07

One Year Ago EPS-$0.24

ITRMF Q3 2025 Revenue Results

Actual Revenue$390.00K

Expected Revenue$0.00

Beat/MissBeat by +$390.00K

YoY Revenue Growth―

Earnings Announcement Details

QuarterQ3 2025

Date11/14/2025

TimeBefore Open

Conference CallFriday, November 14, 2025

ITRMF Upcoming Earnings

Iterum Therapeutics's next earnings date is estimated for November 12, 2026, based on past reporting schedules.

Q3 2025 Earnings Call Audio

ITRMF Q3 2025 Earnings Call

0:00 / 0:00

Q3 2025 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2025 Earnings Call Summary

Q3 2025

Earnings Call Date:Nov 14, 2025|

% Change Since:

Earnings Call Sentiment|Neutral

The earnings call highlighted the successful early stages of Orlynda's launch and positive market feedback, indicating potential for growth. However, financial challenges remain due to limited initial revenue, increased expenses, and the need for additional capital.

Company Guidance

In the third quarter of 2025, Iterum Therapeutics reported net product sales of $400,000 with the launch of Orlynda in the U.S. in August 2025. The company successfully generated over 280 prescriptions through more than 100 unique prescribers, indicating growing physician and patient engagement. Approximately 40% of prescriptions have been filled through payer approval processes, aligning with expectations despite awaiting broader payer coverage. Iterum anticipates 2026 net product revenue to range between $5 million and $15 million, supported by expanding insurance coverage, particularly with a recent signed rebate agreement with a top Medicare Part D pharmacy benefit manager. Operating expenses for 2026 are projected between $25 million and $30 million, with current cash reserves expected to fund operations into 2026. The company aims to raise additional capital to sustain commercialization efforts, targeting high-value territories and potentially expanding further.

Successful Initial Launch of Orlynda

Orlynda was launched on August 20, 2025, and generated more than 280 prescriptions through 100 unique prescribers, with nearly half prescribing to more than one patient.

Positive Physician Feedback

Physicians have shown strong interest in Orlynda as a new treatment option for uncomplicated urinary tract infections, particularly where antibiotic resistance is a challenge.

Advancements in Managed Care and Market Access

Iterum has a signed rebate agreement with a top Medicare Part D pharmacy benefit manager, increasing coverage and access for Orlynda starting in 2026 or 2027.

Patent Expansion

New patents granted in China and Mexico, extending Iterum's intellectual property protection to 2041 and 2039, respectively.

ITRMF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change
Nov 12, 2026	2026 (Q3)	- / -	-0.16	―
Aug 07, 2026	2026 (Q2)	- / -	-0.13	―
May 20, 2026	2026 (Q1)	- / -	-0.1	―
Mar 12, 2026	2025 (Q4)	-0.14 / -0.20	-0.12	-66.67% (-0.08)
Nov 14, 2025	2025 (Q3)	-0.09 / -0.16	-0.24	33.33% (+0.08)
Aug 05, 2025	2025 (Q2)	-0.11 / -0.13	-0.23	43.48% (+0.10)
May 13, 2025	2025 (Q1)	-0.14 / -0.10	-0.38	73.68% (+0.28)
Feb 07, 2025	2024 (Q4)	-0.17 / -0.12	-0.81	85.19% (+0.69)
Nov 14, 2024	2024 (Q3)	-0.17 / -0.24	-1.2	80.00% (+0.96)
Aug 14, 2024	2024 (Q2)	-0.45 / -0.23	-0.77	70.13% (+0.54)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed